Health and medical companies that employ many individuals who are not U.S. citizens seemed unfazed by a change to immigration policies that will increase the amount of time it will take to process their visas.

While biotechnology executives slammed Trump’s executive order barring individuals from seven Muslim-majority countries from traveling to the United States, they have remained mum on a decision by the Department of Homeland Security to temporarily suspend a program that allowed companies to pay a fee to receive visas for employees in 15 days. Normally, it takes months.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • by personal experience, I can say that biotech companies have not been sponsoring visas for international scientists (that are not already in the US on some type of visa) for at least, the past ten years. So, a loss of fast tracking is not really changing the dynamics in any meaningful way

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy